IRS1 and cancer: Furthermore, a recent study reported that treatment with an mTOR inhibitor (WAY-129327) decreased endometrial proliferation, whereas mTOR activation was followed by loss of negative feedback to insulin receptor substrate-1 (IRS-1) during the early stages of cancer development [17].